All companies
ImmuCell Corporation logo

What smart money is saying about ImmuCell CorporationUnited States flag

ICCC · Healthcare · Biotechnology · Market cap $57M

1 fund in our archive has pitched ImmuCell Corporation — most recently SRK Capital in September 2025.

Company profile

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Get an email when a fund writes about it

Fund coverage · 1 thesis

  • SRK Capital
    September 2025

    ImmuCell Corporation is experiencing significant growth with record margins and cash flow, while poised for further expansion due to new product lines and potential FDA approval, despite leadership transitions.

    Read the full thesis

Read every full thesis on ImmuCell Corporation

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans